Avedro, EyeGate Pharma to enter agreement

November 7, 2012

EyeGate Pharma’s broad iontophoresis patent portfolio for corneal collagen cross-linking will be held as exclusive license by Avedro Inc. Delivery approach provides potential additional benefits to current formulation.

Related Content:

News